FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4295957851> ?p ?o ?g. }

• W4295957851 endingPage "102494" @default.
• W4295957851 startingPage "102494" @default.
• W4295957851 abstract "Dietary feeding and stable isotope studies in rodents support that the 24-carbon omega-3 polyunsaturated fatty acids, tetracosapentaenoic acid (24:5n-3, TPAn-3) and tetracosahexaenoic acid (24:6n-3, THA), are immediate precursors to docosahexaenoic acid (DHA, 22:6n-3). In this study, we assessed for the first time, changes in TPAn-3 or THA levels following omega-3 PUFA supplementation in humans, providing insight into human omega-3 PUFA metabolism. In this secondary analysis of a double-blind randomized control trial, women and men (19 – 30 years, n = 10 – 14 per sex, per diet) were supplemented with 3 g/day EPA, DHA, or olive oil control for 12 weeks. Plasma TPAn-3 and THA concentrations were determined by gas chromatography-mass spectrometry to determine changes following supplementation in a sex-specific manner (sex x time). EPA supplementation significantly increased (p < 0.0001) plasma TPAn-3 by 215% (1.3 ± 0.1 – 4.1 ± 0.7, nmol/mL ± SEM) and THA by 112% (1.7 ± 0.2 – 3.6 ± 0.5, nmol/mL ± SEM). Furthermore, women had 111% and 99% higher plasma TPAn-3 and THA in the EPA supplemented group compared to men (p < 0.0001). There were no significant effects of time on plasma TPAn-3 or THA concentrations in the DHA supplemented or olive oil supplemented groups. In conclusion, EPA, but not DHA, supplementation in humans increased plasma TPAn-3 and THA levels, suggesting that THA accumulates prior to conversion to DHA in the n-3 PUFA synthesis pathway. Furthermore, women generally exhibit higher plasma TPAn-3 and THA concentrations compared with men, suggesting that women have a greater ability to accumulate 24-carbon n-3 PUFA in plasma via EPA and DPAn-3 elongation, which may explain the known higher DHA levels in women. Summary: In this secondary analysis of a double-blind randomized control trial, we assessed changes in omega-3 (n-3) tetracosapentaenoic acid (24:5n-3, TPAn-3) and tetracosahexaenoic acid (24:6n-3, THA) plasma levels in women and men (19 – 30 years, n = 10 – 14 per sex, per diet) following 12-weeks of n-3 PUFA supplementation (3 g/day EPA, DHA or olive oil). Women had higher plasma TPAn-3 in all supplementation groups and higher THA levels in the EPA and olive oil groups (p < 0.0001) compared to men. EPA supplementation increased (p < 0.0001) plasma TPAn-3 by 215% (1.3 ± 0.1 – 4.1 ± 0.7, nmol/mL ± SEM) and THA by 112% (1.7 ± 0.2 – 3.6 ± 0.5, nmol/mL ± SEM), but DHA supplementation had no effect. For the first time in humans, we show that plasma TPAn-3 and THA levels are higher in women and increased with EPA, but not DHA supplementation, suggesting an accumulation of THA prior to conversion to DHA in the n-3 PUFA synthesis pathway." @default.
• W4295957851 created "2022-09-16" @default.
• W4295957851 creator A5004767165 @default.
• W4295957851 creator A5007960413 @default.
• W4295957851 creator A5011079449 @default.
• W4295957851 creator A5031244917 @default.
• W4295957851 date "2022-10-01" @default.
• W4295957851 modified "2023-10-18" @default.
• W4295957851 title "Increases in plasma n-3 tetracosapentaenoic acid and tetracosahexaenoic acid following 12 weeks of EPA, but not DHA, supplementation in women and men" @default.
• W4295957851 cites W1583498277 @default.
• W4295957851 cites W1818048492 @default.
• W4295957851 cites W2000176794 @default.
• W4295957851 cites W2036609643 @default.
• W4295957851 cites W2042483003 @default.
• W4295957851 cites W2051097612 @default.
• W4295957851 cites W2138419705 @default.
• W4295957851 cites W2138825852 @default.
• W4295957851 cites W2165822735 @default.
• W4295957851 cites W2167918856 @default.
• W4295957851 cites W2168526937 @default.
• W4295957851 cites W2186476960 @default.
• W4295957851 cites W2216351193 @default.
• W4295957851 cites W2564577771 @default.
• W4295957851 cites W273463978 @default.
• W4295957851 cites W2863458451 @default.
• W4295957851 cites W2886354357 @default.
• W4295957851 cites W2906013156 @default.
• W4295957851 cites W2913310067 @default.
• W4295957851 cites W2914896082 @default.
• W4295957851 cites W2952928229 @default.
• W4295957851 cites W2978279846 @default.
• W4295957851 cites W2998849619 @default.
• W4295957851 cites W3080689030 @default.
• W4295957851 cites W3100935973 @default.
• W4295957851 cites W3133953847 @default.
• W4295957851 doi "https://doi.org/10.1016/j.plefa.2022.102494" @default.
• W4295957851 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36148741" @default.
• W4295957851 hasPublicationYear "2022" @default.
• W4295957851 type Work @default.
• W4295957851 citedByCount "2" @default.
• W4295957851 countsByYear W42959578512022 @default.
• W4295957851 countsByYear W42959578512023 @default.
• W4295957851 crossrefType "journal-article" @default.
• W4295957851 hasAuthorship W4295957851A5004767165 @default.
• W4295957851 hasAuthorship W4295957851A5007960413 @default.
• W4295957851 hasAuthorship W4295957851A5011079449 @default.
• W4295957851 hasAuthorship W4295957851A5031244917 @default.
• W4295957851 hasConcept C126322002 @default.
• W4295957851 hasConcept C134018914 @default.
• W4295957851 hasConcept C140793950 @default.
• W4295957851 hasConcept C185592680 @default.
• W4295957851 hasConcept C19038510 @default.
• W4295957851 hasConcept C2776091944 @default.
• W4295957851 hasConcept C2777171753 @default.
• W4295957851 hasConcept C2988377048 @default.
• W4295957851 hasConcept C31903555 @default.
• W4295957851 hasConcept C543025807 @default.
• W4295957851 hasConcept C55493867 @default.
• W4295957851 hasConcept C62231903 @default.
• W4295957851 hasConcept C71924100 @default.
• W4295957851 hasConcept C86803240 @default.
• W4295957851 hasConceptScore W4295957851C126322002 @default.
• W4295957851 hasConceptScore W4295957851C134018914 @default.
• W4295957851 hasConceptScore W4295957851C140793950 @default.
• W4295957851 hasConceptScore W4295957851C185592680 @default.
• W4295957851 hasConceptScore W4295957851C19038510 @default.
• W4295957851 hasConceptScore W4295957851C2776091944 @default.
• W4295957851 hasConceptScore W4295957851C2777171753 @default.
• W4295957851 hasConceptScore W4295957851C2988377048 @default.
• W4295957851 hasConceptScore W4295957851C31903555 @default.
• W4295957851 hasConceptScore W4295957851C543025807 @default.
• W4295957851 hasConceptScore W4295957851C55493867 @default.
• W4295957851 hasConceptScore W4295957851C62231903 @default.
• W4295957851 hasConceptScore W4295957851C71924100 @default.
• W4295957851 hasConceptScore W4295957851C86803240 @default.
• W4295957851 hasFunder F4320319908 @default.
• W4295957851 hasLocation W42959578511 @default.
• W4295957851 hasLocation W42959578512 @default.
• W4295957851 hasOpenAccess W4295957851 @default.
• W4295957851 hasPrimaryLocation W42959578511 @default.
• W4295957851 hasRelatedWork W1983232135 @default.
• W4295957851 hasRelatedWork W2002621906 @default.
• W4295957851 hasRelatedWork W2004692907 @default.
• W4295957851 hasRelatedWork W2051219433 @default.
• W4295957851 hasRelatedWork W2083247227 @default.
• W4295957851 hasRelatedWork W2095350495 @default.
• W4295957851 hasRelatedWork W2115229762 @default.
• W4295957851 hasRelatedWork W2336136860 @default.
• W4295957851 hasRelatedWork W3027083723 @default.
• W4295957851 hasRelatedWork W2189526387 @default.
• W4295957851 hasVolume "185" @default.
• W4295957851 isParatext "false" @default.
• W4295957851 isRetracted "false" @default.
• W4295957851 workType "article" @default.